Triptolide is a potent Nrf2 inhibitor that can inhibit the transcriptional activity of Nrf2, leading to the apoptosis of isocitrate dehydrogenase (IDH)-mutant cells, providing an operable strategy for the treatment of malignant tumors with IDH1 mutations 51. This evidence concerns the gene IDH1 and cancer.